Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the southwest oncology group
Christopher W. Ryan, Bryan H. Goldman, Primo N. Lara, Philip C. Mack, Tomasz M. Beer, Catherine M. Tangen, Dianne Lemmon, Chong Xian Pan, Harry A. Drabkin, E. David Crawford
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the southwest oncology group'. Together they form a unique fingerprint.